nysenvo
Key Points Wegovy, Novo Nordisk’s weight-loss drug, reduces cardiovascular risk in overweight adults.Patients in the Wegovy clinical trial showed 20% less likelihood of major cardiovascular events.Bank of America notes the news is a “game changer for payor debate on obesity.”B of A analysts anticipate further data to be presented at the American Heart Association conference in November.Wall Street predicts 49% earnings rise in 2023 and 18% in 2024 for Novo.5 stocks we like better than Novo Nordisk A/SWeight-loss drugs are the pharmaceutical industry’s equivalent of AI, in the sense of being a ...
ValueWalk
The biopharmaceutical industry had an exceptional year in 2022 with notable success for those with COVID-19 vaccines. The majority (15) of the top 20 publicly traded global innovative biopharma companies reported a 5.2% growth in the aggregate revenue to $868.97 billion from 2021 to 2022, reveals GlobalData, a leading data and analytics company. Global Biopharma Companies Report YoY GrowthGlobalData reveals that Novo Nordisk (NYSE:NVO), Pfizer (NYSE:PFE) and Merck & Co (NYSE:MRK) reported YoY revenue growth of 25.7%, 23.4% and 21.7%, respectively, in 2022. Pfizer finished first in the top 20 l...
ValueWalk
Supply shortages have complicated the pharmaceutical industry.Eli Lilly & Co are making the right pivots.New partnerships aimed at new products show great promise.The dividend is healthy, and long-term growth looks good.5 stocks we like better than Eli Lilly andHeading into the week before Christmas, the United States Food and Drug Administration flagged Eli Lilly & Co. (NYSE:LLY) for a shortage of their new diabetes drug, Mounjaro. They are also having supply issues with their previous diabetes medicine, Trulicity, which is the pharmaceutical company’s best-selling drug of all time. Q3 2022 h...
ValueWalk
Excluding the impact of currency changes, Novo Nordisk A/S (NYSE:NVO)’s sales during the first nine months of the year rose 13% to 102.5bn Danish Kroner (DKK). This was driven by strong growth in GLP-1 treatments while Biopharm sales saw a modest uptick. Q3 2021 hedge fund letters, conferences and more Operating profit for the period rose 12% to DKK 45bn. The group announced plans to expand its buyback programme by DKK 2bn to DKK 20bn and expects underlying full year sales and operating profit growth between 12% and 15% The shares rose 1.6% following the announcement Novo Nordisk GLP-1 SalesLa...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら